WHO recommends life-saving #interleukin-6 receptor blockers for #COVID-19 and urges producers to join efforts to rapidly increase access https://www.who.int/news/item/06-07-2021-who-recommends-life-saving-interleukin-6-receptor-blockers-for-covid
The prospective and living network meta-analyses showed that in severely or critically ill patients, administering these drugs [Interleukin-6 blocking drugs – #tocilizumab and #sarilumab –] reduce the odds of death by 13%, compared to standard care. This means that there will be 15 fewer deaths per thousand patients, and as many as 28 fewer deaths for every thousand critically ill patients. The odds of mechanical ventilation among severe and critical patients are reduced by 28%, compared with standard care. This translates to 23 fewer patients out of a thousand needing mechanical ventilation.
Source :
Association Between Administration of #IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis
#WHO Rapid Evidence Appraisal for COVID-19 Therapies (#REACT) Working Group et al. JAMA. 2021. https://pubmed.ncbi.nlm.nih.gov/34228774